Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Pursuant to Belgian transparency legislation 1, Galapagos received transparency notifications from Bank of America Corporation on March 5 and 6, 2026. The initial notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for equivalent financial instruments relating to Galapagos’ voting rights on March 3, 2026, as a result of the disposal of such instruments. A subsequent notification received on March 6, 2026 indicates that Bank of America Corporation, as controlling entity, crossed above the 5% threshold for equivalent financial instruments relating to Galapagos’ voting rights again on March 4, 2026, following the acquisition of such instruments.
On March 6, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 335,202 voting rights and 3,489,591 equivalent financial instruments, representing together 5.80% of Galapagos’ currently outstanding 65,897,071 shares.
Summary of the transactions:
Content of the notifications from Bank of America Corporation:
The notification dated March 6, 2026, contains the following information:
The chain of control has been described at the end of the notification (section 11) and can be found here.
Content of the notifications from Bank of America Corporation:
The notification dated March 5, 2026, contains the following information:
The chain of control has been described at the end of the notification (section 11) and can be found here.
About Galapagos
Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.
For further information, contact Galapagos:
Investor Relations
Glenn Schulman
+1 412 522 6239
ir@glpg.com
Media
Media
Katie Morris
+1 952 288 6821
katiemorris@ententeinc.com
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.
Attachment